지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 110 - 125 (16page)
- DOI
- 10.5217/ir.2021.00143
이용수
초록· 키워드
오류제보하기
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods: SELECTION (NCT02914522) was a randomized, placebo-controlled trial comprising 2 induction studies and a maintenance study. Adults with moderately to severely active UC were randomized in induction study A (biologic-naïve) or B (biologic-experienced) to receive filgotinib 200 mg, 100 mg, or placebo once daily for 11 weeks. Patients in clinical remission or Mayo Clinic score response at week 10 entered the 47-week maintenance study. Efficacy and safety outcomes were assessed in Japanese patients enrolled in Japan.
Results: Overall, 37 and 72 Japanese patients were enrolled in Japan in induction studies A and B, respectively, and 54 entered the maintenance study. Numerically higher proportions of filgotinib 200 mg-treated than placebo-treated patients achieved clinical remission in induction study A (4/15 [26.7%] vs. 0/6 [0%]) and the maintenance study (5/20 [25.0%] vs. 0/9 [0%]), but not induction study B (1/29 [3.4%] vs. 1/14 [7.1%]). Both doses were well tolerated, and no new safety signals were noted. Herpes zoster was reported in 1 filgotinib 200 mg-treated patient in each of induction study A (2.3%, 1/44) and the maintenance study (5.0%, 1/20). Conclusions: These data, alongside those of the overall SELECTION population, suggest the potential of filgotinib 200 mg as a viable treatment option for Japanese patients with UC. Owing to small patient numbers, data should be interpreted cautiously.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
Gut and Liver
2022 .05
-
Factors related to Quality of Life of Patients with Ulcerative Colitis
성인간호학회 학술대회
2015 .04
-
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Gut and Liver
2016 .01
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Intestinal research
2021 .10
-
청소년궤양성 대장염 환자의 사상체질요법에 대한 증례보고
대한한방내과학회지
2017 .01
-
Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?
Gut and Liver
2021 .09
-
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Intestinal research
2022 .04
-
One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Intestinal research
2022 .04
-
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Gut and Liver
2021 .11
-
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
Gut and Liver
2016 .01
-
The role and prospect of tofacitinib in patients with ulcerative colitis
Intestinal research
2023 .01
-
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Intestinal research
2019 .01
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
-
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Intestinal research
2023 .01
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
Gut and Liver
2022 .03
-
Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Intestinal research
2023 .04
-
Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Intestinal research
2019 .01
-
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal research
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0